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Novelty statement:  
• This study’s novel results demonstrate that metformin ± insulin treatment is linked to 
the lower incidence of pre-eclampsia than insulin treatment alone in women with 
GDM or Type 2 DM, which is likely to be age-dependent and associated with reduced 
weight gain during pregnancy.  
• Surprisingly, in other high-risk pregnancies where glucose-lowering agents are not 
essential, metformin does not appear to be beneficial.  
• Current clinical guidelines which stipulate insulin treatment as a first line choice in 
pregnancies complicated by diabetes should be reviewed in light of these findings and 
adequately designed RCTs with pre-eclampsia as a primary outcome carried out 
urgently. 
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Abstract 
AIMS 
Hypertensive disorders in pregnancy, particularly pre-eclampsia, are leading causes of 
maternal or foetal morbidity and mortality, and effective treatments are lacking. The aim of 
this study was to perform meta-analyses of studies evaluating the risk of pre-eclampsia in 
high-risk insulin-resistant women taking metformin prior or during pregnancy. 
METHODS 
Medline, EMBASE, Web of Science and Scopus databases were searched. Both randomised 
controlled trials [RCTs] and prospective observational studies of metformin treatment vs. 
placebo/control or insulin, either prior to or during pregnancy, were selected. The main 
outcome measure was the incidence of pre-eclampsia in each treatment group.  
RESULTS 
Overall, in nine studies comparing metformin treatment [n=1,281] to placebo/control 
[n=1,341], no difference in the risk of pre-eclampsia was demonstrated [combined/pooled 
RR=0.98; 95% CI 0.53-1.82; p=0.95; I
2
=54%]. Restricting analysis to five RCTs again 
showed no significant effect [RR=0.86; 95% CI 0.33-2.26; p=0.76; I
2
=66%]. However, a 
meta-analysis of nine studies comparing metformin [n=1,303] to insulin [n=1,235] showed 
reduced risk of pre-eclampsia with metformin [RR=0.71; 95% CI 0.53-0.96; p=0.03; I
2
=0%], 
also seen when analyses were restricted to the eight RCTs [n=1,674; RR=0.68; 95% CI 0.48-
0.95; p=0.02; I
2
=0%]. High levels of heterogeneity were present in studies comparing 
metformin to placebo/control. Pre-eclampsia was a secondary outcome in most of the studies. 
Mean weight gain from enrolment to delivery was lower in metformin group [p=0.05, 
metformin vs. placebo; p=0.004, metformin vs. insulin]. 
CONCLUSIONS  
In studies randomising pregnant women to glucose-lowering therapy, metformin is associated 
with a lower risk of pre-eclampsia than insulin.   
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Introduction  
Pre-eclampsia is a complication of pregnancy that occurs in the second half of gestation. It is 
defined as the new onset, after 20 weeks gestation, of hypertension (≥140/90 mmHg) and 
proteinuria (≥300 mg per 24 h), or in the absence of proteinuria, any of the following: 
thrombocytopenia (platelets<100,000/µl), impaired liver function, progressive renal 
insufficiency, pulmonary oedema or cerebral or visual disturbances[1]. Pre-eclampsia is 
classified according to gestational age at onset: term pre-eclampsia (onset ≥37 weeks), 
preterm pre-eclampsia (34-37 weeks), and early-onset pre-eclampsia (<34 weeks)[2]. Severe 
features of pre-eclampsia include blood pressure ≥160/110 mmHg, thrombocytopenia, 
impaired liver function, progressive renal insufficiency, pulmonary oedema, cerebral or 
visual disturbances[1]. Pre-eclampsia is the leading cause of maternal and foetal morbidity 
and mortality: by conservative estimates, it affects 10 million pregnant women worldwide 
annually, and is responsible for 76,000 maternal and 500,000 infant deaths[3]. In addition to 
the short-term risks, pre-eclampsia is associated, later in life, with cardiovascular disease 
and/or Type 2 diabetes mellitus (Type 2 DM) in both mothers and offspring(4,5).  
The incidence of pre-eclampsia is ~4-6% in the general population, but is greatly increased 
by insulin-resistant disorders such as gestational diabetes (GDM), Type 2 DM, polycystic 
ovary syndrome (PCOS) and obesity(6–8). In women with pre-gestational diabetes, whether 
Type 1 or Type 2 DM, the risk for pre-eclampsia in increased approximately four-fold(9,10).  
There are currently no reliable biomarkers or effective preventative measures, and no 
treatments for pre-eclampsia other than delivery. The pathogenesis of pre-eclampsia is linked 
to aberrant angiogenesis and inadequate remodelling of the spiral uterine artery, later leading 
to the development of an ischemic placenta; however, understanding of underlying 
mechanisms is inadequate, impeding the rational for development of preventative and 
treatment strategies.  
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A few therapeutic approaches have been explored. Low dose aspirin (75 mg daily) may 
reduce the incidence of pre-eclampsia by up to 25% if taken before 16 weeks gestation(11), 
and is recommended from 12 weeks gestation for women who have one or more of the 
following risk factors: history of pre-eclampsia, multifoetal gestation, chronic hypertension, 
diabetes (Type 1 or 2 DM), renal disease or autoimmune disease (e.g. systemic lupus 
erythematous, antiphospholipid syndrome). Anti-oxidant supplements have also been 
assessed, but so far failed to show benefit in the prevention of pre-eclampsia(10).   
Metformin can be safely used in pregnancy[12] enabling investigation of its effects on 
pregnancy outcomes in women who are at higher risk such as obese women or women with 
GDM, Type 2 DM, or PCOS[13–16]. Metformin reduces insulin resistance, and mitigates 
endothelial dysfunction and hyperglycaemia, factors which have been associated with pre-
eclampsia[17,18]. Metformin is an AMPK activator, and reduced AMPK pathway activity 
has also been implicated in the pathogenesis of pre-eclampsia[19,20]. It is established that the 
circulating anti-angiogenic factor, fms-like tyrosine kinase 1 (sFlt-1) is significantly 
increased in pregnancies complicated by pre-eclampsia, and recently, it was demonstrated 
that metformin can reduce sFlt-1 secretion from placental tissue and placental explants[21]. 
Metformin therefore warrants investigation as a preventive treatment for pre-eclampsia.  
The aim of this systematic review and meta-analysis is to evaluate evidence concerning the 
efficacy of metformin compared to placebo/control or insulin in reducing the incidence of 
pre-eclampsia in high-risk pregnant women using randomised controlled trials (RCTs) and 
prospective observational studies or RCTs alone. 
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Methods 
Data sources and searches  
A systematic literature search was conducted using Medline (1946), Embase (1974), Web of 
Science, and Scopus databases for eligible studies from inception until November 2016. 
Filters were not used for the type of study or language, however only studies in human 
populations were included.  In collaboration with the subject librarian (RF) at the Medical 
Library, Queen’s University Belfast, the following terms and keywords were used: a) 
“Metformin or Glucophage”, b) “Pre-eclampsia or Pre-eclamp* or Preeclampsia or 
Preeclamp*” and c) “Gestational hypertension or Pregnancy-induced hypertension”. 
Combinations of a) AND b) or a) AND c) were also used.  
 
Study selection  
Only those studies that met all of the following criteria were considered: 1) original study; 2) 
RCT or prospective observational study/cohort study (CS); 3) women took metformin before 
pregnancy and/or during pregnancy, and 4) women were followed throughout the pregnancy 
and pregnancy outcomes were recorded. We only included studies in which pre-eclampsia 
was diagnosed based on the following criteria: at least two consecutive blood pressure 
measures ≥140/90 mm Hg with proteinuria (≥0.3 g per 24 hours or 2+ on dipstick testing), 
with documented onset after gestational week 20. Three studies were included that defined 
and diagnosed pre-eclampsia in women with new onset hypertension in the absence of 
proteinuria but with one of the following: haematological involvement, liver involvement, 
neurological involvement, pulmonary oedema, foetal growth restriction or placental 
abruption[13,14,22].  
As depicted in the PRISMA flow chart (Fig. 1), the database search and literature screening 
yielded 364 studies. After removing duplicates, two reviewers (AA and LM) screened titles 
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and abstracts of remaining 321 articles. Following initial screening 293 articles were 
excluded because they did not meet the inclusion criteria and were outside of the scope of the 
review. Two reviewers (AA and LM) assessed full text of remaining 28 articles. Three were 
excluded because they repeated findings from another included study. Three studies did not 
clearly define pre-eclampsia. Three studies were excluded because corresponding authors, 
contacted for needed clarification, provided no responses[23–25]. One observational study 
was excluded because of poor matching of BMI in the treatment groups[26]. This yielded 
total number of 18 studies. Selected studies compared treatment with metformin to  or 
healthy control (n=5)[22,27–30] or placebo (n=4)[14,16,31,32] or insulin 
(n=10)[15,22,31,33–39] (one study, with three treatment arms, was included both in 
metformin vs. control and metformin vs. insulin analysis[22]). The groups of women 
recruited into selected studies included women with GDM (n=7)[13,15,22,35–38], Type 2 
DM (n=1)[34], PCOS (n=6)[16,28–30,32,40], obese women (n=2)[14,31], and women with 
both GDM and Type 2 DM (n=2)[37,39].  
 
Data Extraction 
The following data were extracted from the 18 studies selected: study characteristics (author, 
year of publication, country), population characteristics (age, body mass index (BMI) at 
enrolment, blood pressure at baseline, weight change during pregnancy, glycaemic control), 
treatment design (number of women on metformin or placebo///insulin, dose of metformin 
and duration of treatment) and outcomes (primary and secondary outcomes) Table 1.   
 
Quality Assessment 
Quality assessment of the included studies was independently performed by two reviewers 
(AA and LM) using Critical Appraisal Skills Programme [CASP, c/o Better Value Healthcare 
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Ltd, Oxford] tools specifically designed for RCTs and CSs. Assessment was based on the 
eleven criteria, with one point being awarded for each if met in the study. The eleven criteria 
were: 1) the aim of the study, 2) randomisation or appropriateness of the method used, 3) 
blinding, 4) patient recruitment and baseline characteristics, 5) equal treatment of the groups, 
6) follow-up of the women, 7) the significance of the results, 8) the precision of the results, 9) 
ability to apply results locally, 10) primary and secondary outcomes, and 11) whether benefit 
is worth the harm and costs or whether the results fit other available evidence. The scores 
were compared between the two reviewers (AA and LM) and any significant differences 
discussed individually.  
Assessing the risk of bias was only possible for RCTs. We used RevMan 5.3 (Cochrane, UK) 
software which automatically generated a panel representing overall risk of bias for each 
study based on A) random sequence generation, B) allocation and concealment, C) blinding 
of participants and personnel, D) blinding outcome assessment, E) incomplete outcome data, 
F) selective reporting and G) other bias.   
 
Data synthesis and analysis 
Risk ratio (RR) and accompanying standard errors were extracted from each study in relation 
to pre-eclampsia. In each, unadjusted estimates were recorded. A meta-analysis was 
performed to obtain pooled RR for pre-eclampsia in pregnant women treated with metformin 
compared with placebo/control or insulin. Patient clinical characteristics which have shown a 
positive association with pre-eclampsia (e.g. age, BMI and blood pressure at enrolment; mean 
fasting blood glucose (FBG) from enrolment to delivery; HbA1c at 36-37 weeks; GDM 
incidence; mean weight gain from enrolment to delivery) where available, were used to 
perform a meta-analysis to obtain pooled standard mean differences in pregnant women 
treated with metformin compared with placebo/control or insulin. Therefore, two separate 
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analyses were performed to compare effects of metformin vs. placebo/control and metformin 
vs insulin on the incidence of pre-eclampsia. In our analyses, any patient on metformin who 
subsequently needed insulin to maintain good glycaemic control during the course of the 
pregnancy was included in the metformin arm.  
Random effects models were used to combine estimates to account for any heterogeneity 
present in the studies. Heterogeneity among studies was tested using a Chi-squared test and 
measured using the I-squared statistic. RevMan 5.3 software (The Nordic Cochrane Centre, 
The Cochrane Collaboration, Copenhagen, Denmark) and Stata 12 software (StataCorp LP, 
College Station, TX) were used to carry out these analyses. First, both RCTs and CSs were 
included in the meta-analyses. Following this, only RCTs were included in the meta-analyses. 
Publication bias was assessed by funnel plots representing the log RR against the standard 
error[41].  
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Results 
Study characteristics  
Characteristics of the 18 selected studies are described in detail in Table 1. Fourteen 
RCTs[13–16,30–39] and four CSs[22,28,29,40] studies were included. The baseline age 
range for all the women (n=3,374) was 16-46 years; most of the studies included women less 
than 35 years old. The majority of women were overweight (BMI: 25-30 kg/m², 35%) or 
(BMI>30 kg/m², 64%); only 1% had normal BMI at enrollment. Metformin treatment was 
initiated before pregnancy in three studies[28,29,40], all in women with PCOS, in whom the 
aim was to enhance fertility. Pre-eclampsia was reported as a primary outcome in three 
studies[16,29,40] and as a  secondary outcome in fifteen[13–15,22,28,30–39]. All studies 
were published in or after the year 2000. The studies were carried out worldwide: Australia 
(n=1); Brazil (n=1); Finland (n=2); Ghana (n=1); Italy (n=1), Iran (n=2); New Zealand (n=2); 
Norway (n=2); Pakistan (n=2); UK (n=2); USA (n=3).    
 
Meta-analysis of pre-eclampsia incidence 
A meta-analysis of nine studies[14,16,22,28–32,40] comparing the effects of metformin vs. 
control (placebo//healthy pregnancy) included 2,622 pregnant women (1,281 in the 
metformin group, and 1,341 in the control group; Fig. 2a). The incidence of pre-eclampsia 
was equal in both groups with a RR in the treatment arm of 0.98 (95% CI 0.53-1.82; p=0.95). 
There was significant heterogeneity among these nine studies (I²=54%, p=0.03). Three 
observational studies compared women with PCOS taking metformin with healthy controls 
which yielded similar pre-eclampsia incidence therefore suggesting possible benefit of 
metformin in PCOS cohort of pregnant women[28,29,40]. Due to a difference in study design 
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between RCTs and observational studies, we also performed meta-analyses using the more 
rigorous RCTs only, in order to reduce heterogenity. A meta-analysis of metformin vs. 
placebo/control included five RCT studies[14,16,30–32] with a total of 1,220 pregnant 
women (611 on metformin treatment and 609 on placebo/control; Fig. 2b). Again, there was 
no diffeence in the incidence of pre-eclampsia between pregnant women taking metformin vs. 
placebo/control group (RR=0.86, 95% CI 0.33-2.26; p=0.76), and despite exclusion of 
observational studies there was still significant heterogeneity among the studies (I²=66%, 
p=0.02).  
When the effects of metformin vs. insulin were compared, following exclusion of one 
RCT[38] in which a high risk of bias was dicovered (RevMan 5.3 risk of bias assessment), an 
overall meta-analysis of nine studies[13,15,22,33–37,39] was performed. This meta-analysis 
included 2,538 pregnant women (1,303 on metformin treatment and 1,235 on insulin 
treatment) demonstrated a reduction in pre-eclampsia incidence associated with metformin 
(RR=0.71; 95% CI 0.53-0.96, p=0.03; Fig. 2c). There was no heterogeneity among these 
studies in relation to pre-eclampsia incidence (I²=0%). A meta-analysis of RCTs only that 
compared the use of metformin vs. insulin during pregnancy in eight studies[13,15,33–37,39] 
including 1,674 pregnant women (838 on metformin treatment, and 836 on insulin), found 
that the incidence of pre-eclampsia was lower by over 30%, in the metformin group 
(RR=0.68; 95% CI 0.48-0.95, p=0.02; Fig. 2d) with no heterogeneity between the studies in 
relation to pre-eclampsia incidence (I²=0%). All meta-analyses performed, associated forest 
and funnel plots, and the risk of bias assessment for RCTs are summarized in Fig. 2.   
 
Meta-analyses of clinical characteristics associated with pre-eclampsia 
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Considering that advanced age, BMI, blood pressure, GDM, glycemic control in women with 
diabetes and weight gain during pregnancy have all been strongly and independently 
associated with pre-eclampsia[2,9,17,42–44], we evaluated differences in these factors 
between metformin and control or insulin groups. BMI has been strongly linked to pre-
eclampsia with the incidence typically doubling with each 6 kg/m
2
 increase in pre-pregnancy 
BMI[17]. Advanced age, higher blood pressure at enrollement and GDM are all 
independently associated with an increase in the incidence of pre-eclampsia[2,43,45]. 
Furthermore, good glycemic control in both GDM and Type 2 DM has also been linked to 
reduced incidence of pre-eclampsia[42]. Mean weight gain from enrollment to delivery was 
recorded in three studies comparing metformin to placebo[14,16,31] and seven studies 
comparing metformin to insulin[13,15,33–37]. 
Metformin vs. placebo/control. A borderline difference in age (p=0.07, Fig. 3a) was observed 
between metformin and placebo/control treatment groups when both RCTs and CSs were 
combined in the meta-analysis. Restricting meta-analysis to RCTs only, showed no difference 
in age between the groups (p=0.21; Fig. 3b). Similarly to age, a meta-analysis including both 
RCTs and CSs showed significant difference in BMI between metformin and placebo/control 
groups (p=0.006, Fig. 3c). This was not surprising as three CSs compared PCOS population 
taking metformin to healthy controls[28,29,40]. High heterogeneity was present between the 
studies in relation to age and BMI. However when meta-analysis was restricted to four 
RCTs[14,16,31,32] only, there was no difference in BMI between metformin and placebo 
groups (p=0.23, Fig. 3d) and heterogeneity disappeared (I
2
=0%). One RCT did not report 
individual baseline parameters in each group but commented that these were homogenous 
between metformin and placebo group[30]. 
In relation to the baseline blood pressure, no difference in systolic or diastolic blood pressure 
was found between metformin and placebo group when three studies[16,31,32] which 
Page 11 of 40 Diabetic Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12 
 
recorded these parameters were included in the meta-analysis (systolic, p=0.78, Fig. 3e; 
diastolic, p=0.62; Fig. 3f). 
Furthermore, in terms of the incidence of dysglycaemia in PCOS and obese women, no 
difference was found in the number of GDM cases between metformin and placebo/control 
group when we included both RCTs and CSs (n=1236 in metformin group and n=1417 in 
placebo/control group; RR=0.93, 95% CI 0.71–1.2, p=0.57; Fig. 4a) or when we restricted 
analysis to RCTs only (n=522 in metformin group and n=499 in placebo group; RR=0.89, 
95% CI 0.69-1.16, p=0.4; Fig. 4b). Heterogeneity between the studies was small (I
2
=27%; 
when RCTs and CSs were combined) or absent (I
2
=0%, RCTs only). 
When meta-analysis using pooled mean weight gain from three RCTs[14,16,31] comparing 
metformin to placebo was performed, borderline significance was achieved in favour of 
metformin (p=0.05; Fig. 4c). Heterogeneity amongst the studies was very high (I
2
=93%) 
therefore it is difficult to interpret this finding. 
Metformin vs. insulin. No difference was detected in age between metformin and insulin 
groups [p=0.58, Fig. 5a]. A meta-analysis of seven RCTs comparing BMI at enrollment 
showed no statistically significant difference between metformin and insulin groups (p=0.63; 
Fig. 5b).  
In terms of glycaemic control we investigated differences in mean FBG and HbA1c between 
metformin and insulin groups from enrollment until week 36-37. The mean FBG was 
recorded in six studies[13,15,34,36,37,39] whereas HbA1c was recorded in five 
studies[13,15,33,36,37]. There were no significant differences between metformin and insulin 
treatment groups in relation to FBG (p=0.36; Fig. 5c) and HbA1c (p=0.73, mmol/mol, Fig. 
5d; p=0.75, %, Supplementary Fig. S1). It is important to note that the percentage of women 
in metfomin group who subsequently received insulin ranged from 14-85% (Supplementary 
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Table S1). The two biggest studies reported that, between them, 46% of women in the 
metformin groups received supplementary insulin[13,22].  
Furthermore, there was substantial variation in the way that weight gain was recorded, so that 
mean weight gain could only be included from four out of seven studies which included 
metformin and insulin groups, in the meta-analysis[13,33,36,37]. These studies recorded 
weight gain from enrolment to delivery. A meta-analysis performed using pooled mean 
weight gain from entry demonstrated that women on metformin were less likely to gain 
weight during pregnancy than women on insulin (p=0.004; Fig. 5e).   
Unfortunately, we were unable to obtain baseline blood pressure data in these studies. None 
of the studies had pre-eclampsia as a primary outcome. 
High heterogeneity was reported within the studies in relation to the following clinical 
parameters that were included in the meta-analyses: Age (I
2
=82%), BMI (I
2
=80%), FBG (I
2
= 
66%), HbA1c (I
2
=80%) and mean weight gain (I
2
=78%). 
 
Discussion  
In this systematic review, we analysed and critically appraised clinical studies which 
compared the use of metformin treatment with placebo/control or insulin treatment in 
pregnant women with insulin-resistant disorders such as PCOS, obesity, Type 2 DM and 
GDM. Such women are at higher risk of developing complications of pregnancy including 
pre-eclampsia. We performed two different meta-analyses: 1) including RCTs and 
prospective observational studies or CSs, and 2) including RCTs only. We also carried out 
two separate analyses comparing metformin to placebo/control and metformin to insulin.  
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Metformin vs. placebo/control.  The results obtained suggest that there is no difference in the 
incidence of pre-eclampsia between women given metformin vs. placebo/control. We 
recognize that in the RCTs, the presence of a placebo arm implies that a hypoglycaemic agent 
was not clinically mandated (e.g. PCOS and obese cohorts), and therefore eligible participants 
are likely to have lesser risk factors than those requiring randomisation to metformin vs. 
insulin (Type 2 DM and GDM cohorts). Limitations of some studies included comparison of 
metformin-treated women with PCOS to healthy pregnant controls[28,29,40]. This was 
reflected in the meta-analysis of clinical characteristics which found age and BMI to be 
higher in metformin vs. placebo/control groups when both RCTs and CSs were included in 
the analysis. Higher age and BMI are confounding factors for the risk of pre-eclampsia. 
However, when RCTs were only included in the analysis, there was no difference in age or 
BMI between metformin and placebo group. Another limitation was that pre-eclampsia was 
the primary outcome in only three of nine studies, two observational[29,40] and one 
RCT[16]. The heterogeneity between studies was also high. 
Only two studies comparing metformin to placebo recruited obese women with BMI> 30 
kg/m
2
 and without diabetes, but interestingly, although of similar size, the two reached 
opposite conclusions[14,31]. In one, the number of women with pre-eclampsia was 
significantly lower in metformin group (odds ratio [OR] = 0.24; p=0.001)[14] whereas in the 
other, although statistical significance was not reached, a higher incidence of pre-eclampsia 
was reported in metformin group (OR=2.39; p=0.21)[31]. The baseline characteristics of the 
participants in both studies were very similar except that one study included all white 
women[31] whereas the other study included all racial groups and therefore was more 
representative of the general population[14]. In the latter study lower incidence of pre-
eclampsia was observed in metformin group compared to placebo.  In both pre-eclampsia was 
recorded as a secondary outcome.   
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Furthermore, the incidence of GDM was not different between metformin and 
placebo/control groups whether RCTs and CS were combined or when the analysis was 
restricted to RCTs alone suggesting that metformin did not have a significant effect on 
preventing GDM. Women who develop GDM have higher incidence of pre-eclampsia[17] 
therefore it is possible that metformin in these cohorts of women was unable to prevent GDM 
and, as a result, no difference in pre-eclampsia incidence was observed. On the other hand, 
weight gain, which was only reported in three RCTs[14,16,31], was borderline significant in 
favour of metformin. Therefore, the effect of metformin on weight gain appears to be more 
pronounced in people with DM vs. without DM. 
Despite the fact that metformin activates the AMPK pathway, an effect which has been 
shown to inhibit processes directly relevant to the pathogenesis of pre-eclampsia such as 
irregular angiogenesis, endothelial dysfunction and inappropriate placental development[19–
21], it did not demonstrate superiority over placebo/control in reducing the incidence of pre-
eclampsia in this meta-analysis. Interestingly, Vanky and colleagues reported that severe 
pregnancy complications, which included pre-term delivery before 32 weeks, severe pre-
eclampsia or serious post-partum events occurred only in placebo group (placebo, 7/22 vs. 
metformin, 0/18, p=0.01)[32]. Therefore, the effect of metformin vs. placebo on severe pre-
eclampsia should be investigated in the future. 
Interestingly, clinical studies which assessed cardiovascular effects of metformin in people 
without Type 2 DM showed little or no effect on the markers of cardiovascular disease[46]; 
the Diabetes Prevention Program also demonstrated no beneficial effect of metformin in 
reducing the incidence of hypertension in people without Type 2 DM[47]. Conversely, in 
people with Type 2 DM the cardiovascular benefits of metformin were well substantiated in 
the UKPDS trial[48]. This differential effect of metformin in people with vs. without DM 
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could also be relevant to pre-eclampsia, a disease of cardiovascular system, characterised by 
hypertension and proteinuria. 
Metformin vs. Insulin.  The comparison between metformin and insulin demonstrated a 
reduction in RR of pre-eclampsia in favour of metformin whether RCTs and CS were 
combined or when the analysis was restricted to RCTs alone. This result is convincing 
considering there was no heterogeneity between the studies. Nevertheless, in these studies, a 
common weakness was that neither the investigators nor the participants were blinded 
because of the different routes of administration of the study drugs. Most of the risk factors 
for pre-eclampsia, such as age, BMI and glycaemic control were similar between groups at 
the start or throughout the trial; weight gain after enrolment was significantly lower in 
metformin group. Weight gain has been linked to an increased risk of pre-eclampsia[49]. 
Other possibilities for bias included a high risk for random sequence generation, and 
allocation concealment which was present in three studies[15,34,38].  
Considering all studies, on average 45% of the women in the metformin group needed 
supplementary insulin (Supplementary Table S1). When we carried out meta-analysis 
comparing metformin alone vs. insulin alone, which included seven studies [five RCTs; 
Supplementary Fig. S2a,b], the incidence of pre-eclampsia remained lower in the metformin 
group but significance was lost (p=0.18, RCTs and CSs; p=0.21; RCTs only). Administration 
of aspirin was not reported in any of the studies included. Nevertheless, most of these studies 
are relatively small, and therefore there may still be justification for a larger study with pre-
eclampsia as a primary outcome, to address the question definitively.   
Overall, even though metformin ± insulin vs. insulin alone was associated with a lower risk 
for pre-eclampsia, it is unclear whether this is because insulin itself might increase the risk of 
pre-eclampsia, perhaps in part by causing the weight gain, or whether this is a beneficial 
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effect of metformin. A large population-based register data in Finland[45] compared 
pregnancy outcomes in women with GDM who were either under or over 35 years old vs. 
women without GDM in the same age groups. Women with GDM were treated with diet or 
insulin. We calculated RR for pre-eclampsia, based on the data presented in the paper, 
between women with GDM treated on diet vs. insulin treatment in both age groups. This 
showed that in women with GDM who were less than 35 years old, insulin [238/2845] 
increased the risk of pre-eclampsia (RR=1.19; CI 1.04 – 1.36; p=0.0092) compared to diet  
[1161/19422]; no difference was found in the prevalence of pre-eclampsia between diet and 
insulin group in women with GDM who were more than 35 years old. Most of the women 
(>90%) in our meta-analysis were less than 35 years old, which suggests that metformin 
could only have marginal effect on preventing the risk of pre-eclampsia however it is still a 
better option than insulin alone in terms of the risk of pre-eclampsia and possibly other 
pregnancy complications. Further trials are needed to explore the incidence of pre-eclampsia 
between insulin and diet interventions. Perhaps perspective studies comparing insulin 
treatment to diet in women with GDM or Type 2 DM could address this question. It is 
possible that metformin could have advantages over insulin in pregnant women who require a 
hypoglycaemic agent; these advantages could be even more pronounced in women over the 
age of 35 according to the findings by Lamminpää and colleagues[45]. Nevertheless, these 
women might still need insulin supplementation in the later stages of pregnancy to control 
hyperglycaemia. In women on metformin ± insulin, the weight gain is less than in women on 
insulin alone, and it is likely that the dose of insulin may be lower when metformin is used: 
both factors are potentially beneficial in relation to pre-eclampsia. In contrast, in the studies 
comparing metformin with placebo or no treatment, hypoglycaemic intervention was either 
optional or not needed: in these women, the data show no evidence in favour of metformin in 
reducing risk for pre-eclampsia. It is important to explore further the effects of metformin vs. 
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placebo/control on the early or severe type of pre-eclampsia characterised by onset of pre-
eclampsia before 34 weeks gestation or blood pressure ≥160/110 mmHg, respectively. It is 
possible, as suggested by Myatt and colleagues, that there are different phenotypes of pre-
eclampsia and that this is the reason why large clinical studies have failed to validate findings 
observed in smaller studies. Therefore correct stratification of high-risk women according to 
age, presence of diabetes, blood pressure or BMI is important and this could determine the 
most appropriate preventative treatment. Also, women with GDM or Type 2 DM during 
pregnancy are frequently given or swapped to insulin instead of metformin. These women are 
at high risk of pre-eclampsia, it is possible, based on this review, and other published data, 
that metformin ± supplementary insulin would be a better option during pregnancy in these 
women than insulin alone. 
Clearly, in this systematic review we could not include (and did not find) any studies of 
pregnancy in Type 1 DM women. These women also have a four-fold increased risk of 
developing pre-eclampsia, similar to women with Type 2 DM[9,10]. Considering that 
metformin in addition to insulin appears beneficial compared to insulin alone, future 
randomised double-blind placebo-controlled trials investigating the ability of metformin, in 
addition to insulin, in prevention of pre-eclampsia in pregnant women with Type 1 DM could 
be valuable. In the current analysis, with a pre-eclampsia rate of 20% in the insulin group and 
14% in the metformin group (estimated based upon a 30% reduction in metformin group 
observed in this meta-analysis), 650 women with pre-gestational Type 1 DM would need to 
be recruited in each group to have over 80% power to detect this difference as statistically 
significant. 
 
Conclusion 
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In pregnant women requiring hypoglycaemic treatment, metformin alone or metformin in 
combination with insulin is associated with less weight gain and a lower incidence of pre-
eclampsia than insulin alone. This suggests that metformin ± supplementary insulin treatment 
is linked to more favourable pregnancy outcomes such as reduced risk of pre-eclampsia than 
insulin alone. This effect is likely to be age-dependent and associated with reduced weight 
gain during pregnancy. In other high-risk pregnancies where glucose-lowering agents are not 
essential, we did not find a case for prescribing metformin. Considering that metformin can 
safely be used in pregnancy, adequately designed and powered RCTs which have pre-
eclampsia as a primary outcome should be carried out in the future in GDM or Type 2 DM, 
and perhaps in Type 1 DM pregnancies.  
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Table 1. Study characteristics and outcomes measured. 
Figure 1. PRISMA Guidelines flow diagram.  
Figure 2. Meta-analysis comparing the risk ratio of pre-eclampsia in metformin vs. non-
metformin treatment group. [A] A meta-analysis including both RCTs and cohort studies 
[CSs] comparing metformin to placebo/control. [B] A meta-analysis including both RCTs and 
CSs comparing metformin to insulin. [C] A meta-analysis of only RCTs comparing 
metformin to placebo/control. [D] A meta-analysis of only RCTs comparing metfomin to 
insulin. Random effects models were used to combine estimates and analyses were carried 
out using RevMan 5.3 software; risk ratio was calculated; the overall effect was measured 
using Z-test with p values less than 0.05 being statistically significant. Heterogeneity was 
calculated using Chi
2
 test and measured by I
2
 statistic. 
 
Figure 3. Meta-analyses of age, BMI and blood pressure in metformin vs. placebo 
treatment group. [A] A meta-analysis of both RCTs and CSs comparing age between 
metformin and placebo/control group. [B] A meta-anaylsis of RCTs comparing age between 
metformin and placebo group. [C] A meta-analysis of body mass index [BMI] at enrolement, 
RCTs and CS combined. [D] A meta-analysis of body mass index [BMI] at enrolement, RCTs 
only. Meta-analysis of systolic [E] and diastolic [F] blood pressure at baseline between 
metformin and placebo group. Random effects models were used to combine estimates and 
analyses were carried out using RevMan 5.3 software; standard mean difference or risk ratio 
was calculated; the overall effect was measured using Z-test with p values less than 0.05 
being statistically significant. Heterogeneity was calculated using Chi
2
 test and measured by 
I
2
 statistic. 
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Figure 4. Meta-analyses of the incidence of GDM and weight gain in metformin vs. 
placebo treatment group. [A] A meta-analysis comparing the risk ratio of gestational 
diabetes [GDM] between metformin and placebo/control group, RCTs and CS combined. [B] 
A meta-analysis comparing the risk ratio of GDM between metformin and placebo/control 
group, RCTs only. [C] A meta-analysis of weight gain between enrolment and delivery. 
Random effects models were used to combine estimates and analyses were carried out using 
RevMan 5.3 software; standard mean difference or risk ratio was calculated; the overall effect 
was measured using Z-test with p values less than 0.05 being statistically significant. 
Heterogeneity was calculated using Chi
2
 test and measured by I
2
 statistic. 
 
Figure 5. Meta-analyses of patient clinical risk factors for pre-eclampsia in metformin 
vs. insulin treatment group, RCTs only. [A] A meta-analysis of age. [B] A meta-analysis of 
BMI at enrolment. [C] A meta-analysis of mean fasting blood glucose [FBG] from enrolment 
to delivery. [D] A meta-analysis of glycated haemoglobin [HbA1c, mmol/mol] recorded 
between 36 and 37 weeks. [E] A meta-analysis of weight gain between enrolment and 
delivery. Random effects models were used to combine estimates and analyses were carried 
out using RevMan 5.3 software; standard mean difference was calculated; the overall effect 
was measured using Z-test with p values less than 0.05 being statistically significant. 
Heterogeneity was calculated using Chi
2
 test and measured by I
2
 statistic.  
 
Supplementary Table 1. Percentage of patients in metformin group who were supplemented 
with additional insulin. 
 
Supplementary Fig. 1. Meta-analyses of HbA1c [%] in metformin vs. insulin treatment 
group, RCTs only. A meta-analysis of glycated haemoglobin [HbA1c] recorded between 36 
and 37 weeks. Random effects models were used to combine estimates and analyses were 
carried out using RevMan 5.3 software; standard mean difference was calculated; the overall 
effect was measured using Z-test with p values less than 0.05 being statistically significant. 
Heterogeneity was calculated using Chi
2
 test and measured by I
2
 statistic. 
 
Supplementary Fig. 2. A meta-analysis comparing the risk ratio of pre-eclampsia in 
metformin only vs. insulin treatment group. [A] A meta-analysis including both randomised 
controlled trials [RCTs] and cohort studies [CSs] comparing metformin only treatment to 
insulin only treatment. [B] A meta-analysis including only RCTs comparing metformin only 
vs. insulin only treatment. 
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Table 1: Study characteristics and outcomes measured. 
 
Author(year)/ 
Country 
Trial 
type 
Patient 
cohort 
Age 
(range) 
BMI 
(kg/m
2
) 
No. of 
patients 
on 
metformin 
± insulin 
No. of 
patients on 
non-
metformin 
treatment 
Dose of 
metformin 
Duration of 
the 
treatment 
Primary outcomes Secondary 
outcomes 
Glueck et al. 
2004/USA
48
 
CS PCOS 
 
28-38 26-42 97 252  
(control*) 
1500-
2550 
mg/day 
Pre-
conception 
until 
delivery 
Pre-eclampsia GDM 
De Leo et al. 
2011/Italy
37
 
CS PCOS 26-38 26-30 98 110  
(control*) 
1700-
3000 
mg/day 
3–4 months 
before 
infertility 
treatment 
was 
Miscarriage/GDM/ 
Pre-eclampsia/PIH 
N/A 
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initiated 
until 37-
week 
gestation. 
Glueck et al. 
2013/USA
36
 
 
 
 
CS PCOS 28-34 
 
 
 
 
29.4-
39.3 
76 156 
(control*) 
2000-
2550 
mg/day 
On average 
6.8 months 
before 
conception 
until 
delivery 
Miscarriage GDM/ 
Pre-
eclampsia 
Goh et al. 
2014/ New 
Zealand
30
 
CS GDM N/A N/A  465 
metformin  
399  
(insulin) 
2500-
3000 
mg/day 
From 25-29 
weeks 
gestation 
until 
delivery 
Caesarean delivery/ 
Preterm birth 
PIH/ 
Pre-
eclampsia 
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Vanky et al. 
2004/Norway
40
 
RCT Pregnant 
women 
with 
PCOS 
24.4-
32.8 
23.3-
37.9 
18 22  
(placebo) 
850-1700 
mg/day 
From 8 
weeks 
gestation 
until 
delivery 
Dehydroepiandrosterone 
sulfate (DHEAS), 
androstenedione, 
testosterone, SHBG and 
free testosterone index 
(FTI) 
GDM/ 
Pre-
eclampsia 
 
Rowan et al.  
2008/ New 
Zealand & 
Australia
18
 
RCT GDM 28.1-
38.9 
26.8-
43.4 
363  370  
(insulin) 
500-2500 
mg/day 
From 20-33 
weeks 
gestation 
until 
delivery. 
Neonatal complications PIH/ 
Pre-
eclampsia 
Ijas et al. 
2010/Finland
43
 
RCT GDM 25.6-
37.8 
25.4-
36.2 
47 50  
(insulin) 
750-2250 
mg/day 
From 26-34 
weeks 
gestation 
until 
delivery 
Macrosomia Neonatal 
complication/ 
Pre-
eclampsia 
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Vanky et al. 
2010/Norway
21
 
RCT PCOS 25.2-
34 
22.5-
36.5 
135 135 
(placebo) 
2000 
mg/day 
From 5-12 
weeks 
gestation 
until 
delivery 
GDM/ 
Pre-eclampsia 
 
N/A 
Niromanesh et 
al. 2012/Iran
44
 
RCT GDM 25.2-
36.2 
24.1-
32.1 
80 80  
(insulin) 
1000-
2500 
mg/day 
From 20-34 
weeks 
gestation 
until 
delivery 
Maternal glycemic 
control/ 
Birth weight 
PIH/ 
Pre-
eclampsia 
Hickman et al. 
2012/USA
45
 
RCT T2D/GDM  26-37 27-41 14 14 
 (insulin) 
500-2500 
mg/day 
From 10-22 
weeks 
gestation 
until 
delivery 
Glycemic control Maternal and 
neonatal 
outcomes/  
Pre-
eclampsia 
Jamal et al. RCT PCOS 18-40 N/A  35 35 2000 From 6-12 Mean Uterine Artery/ Pre-
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2012/Iran
38
 (control**) mg/day weeks 
gestation 
until 
delivery 
Pulsatility Index eclampsia 
Spaulonci et al. 
2013/Brazil
46
 
RCT GDM 25.9-
37.9 
27.2-
36.7 
46 46 
(insulin) 
1700-
2550 
mg/day 
From 26-34 
weeks 
gestation 
until 
delivery 
Glycemic control Pre-
eclampsia 
Tertti et al. 
2013/Finland
41
 
RCT GDM 26.9-
36.9 
23.5-
35.3 
110  107 
 (insulin) 
500-2000 
mg/day 
From 22–34 
weeks 
gestation 
until 
delivery 
Mean birth weight PIH/ 
Preeclampsia 
Ainuddin et al. 
2015 
RCT GDM 27-35 N/A 75 
 
75 
(insulin) 
500-2500 
mg/day 
From 20-36 
weeks 
Mean birth weight PIH/ 
Pre-
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a/Pakistan
20
 gestation 
until 
delivery 
eclampsia 
Ainuddin et  al. 
2015 
b/Pakistan
42
 
RCT T2D 28.9-
34.6 
28-42 106 100  
(insulin) 
500-2500 
mg/day 
From the 
first 
trimester to 
delivery 
Perinatal death/ 
Birth weight 
PIH/ 
Pre-
eclampsia 
Chiswick et al. 
2015/UK
39
 
RCT Obese >16  >30  221 222 
(placebo) 
500-2500 
mg/day 
From 12-16 
weeks 
gestation 
until 
delivery. 
Median birth-weight Z 
score (IQR) 
Maternal 
insulin 
resistance/ 
Pre-
eclampsia 
Beyuo et al. 
2015/Ghana
47
 
RCT T2D/GDM  28.5-
38.17 
26.52-
40.42 
43 40 
(insulin) 
500-2500 
mg/day 
From 20-30 
weeks 
gestation 
until 
Glycemic control Pre-
eclampsia 
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delivery 
Syngelaki et al. 
2016/UK
19
 
RCT Obese 27.3-
36.2 
36.5-
36.2 
202 198 
(placebo) 
3000 
mg/day 
From 12-18 
weeks 
gestation 
until 
delivery 
Median birth-weight Z 
score (IQR) 
PIH/ 
Pre-
eclampsia 
 
CS: cohort study; RCT: randomized controlled trial; T2D: Type 2 diabetes; GDM: gestational diabetes mellitus; PCOS: Polycystic 
ovary syndrome; BMI: body mass index; PIH: pregnancy induced hypertension; control*: healthy control group; control**: no 
intervention 
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Total number of studies identified 
Medline n=22 
Embase n=15 
Web of science n=45 
Scopus n= 270 
From bibliography n=12 
  
Duplicates removed n=43 
Potentially relevant studies identified 
n=321 
Studies not meeting inclusion 
criteria based on content of title 
and abstract n=293 
Full-text studies assessed for 
eligibility n=28 
Poorly defined outcome n=3 
Poorly matched groups n=1 
Duplicate studies n=3 
No desirable outcome n=3 
  
  
Studies included in systematic review n=18 
T2D n=1 Obesity n=2 GDM n=7 PCOS n=6 GDM&T2D n=2 
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a 
b 
c 
d 
Metformin vs. Placebo/Control; RCTs and CS  
Metformin vs. Placebo/Control; RCTs only 
Metformin vs. Insulin; RCTs and CS  
Metformin vs. Insulin; RCTs only 
c 
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 BMI (metformin vs. placebo/control; RCTs and CSs) c 
d  BMI (metformin vs. placebo; RCTs only) 
Age (metformin vs. placebo/control, RCTs and CS) 
Age (metformin vs. placebo, RCTs only ) b 
a 
 Systolic blood pressure (metformin vs. placebo; RCTs only) 
Diastolic blood pressure (metformin vs. placebo; RCTs only) 
e 
f 
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a GDM (metformin vs. placebo/control; RCTs and CSs) 
 GDM (metformin vs. placebo; RCTs only) b 
 Mean weight gain (metformin vs. placebo; RCTs only) c 
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BMI (kg/m2;metformin vs. insulin; RCTs only) 
Fasting blood glucose (mg/dl; metformin vs. insulin; RCTs only) 
Mean weight gain after entry (kg; metformin vs. insulin; RCTs only) 
HbA1c (mmol/mol; metformin vs. insulin; RCTs only) 
a 
c 
d 
e 
b 
Age (metformin vs. insulin; RCTs only) Page 37 of 40 Diabetic Medicine
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HbA1c (%; metformin vs. insulin; RCTs only) 
Supplementary Fig. S1. Meta-analyses of HbA1c (%) in metformin vs. insulin treatment group, RCTs 
only. A meta-analysis of glycated haemoglobin (HbA1c) recorded between 36 and 37 weeks. Random 
effects models were used to combine estimates and analyses were carried out using RevMan 5.3 software; 
standard mean difference was calculated; the overall effect was measured using Z-test with p values less 
than 0.05 being statistically significant. Heterogeneity was calculated using Chi2 test and measured by I2 
statistic.  
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Study No. of patients on metformin alone No. of patients on metformin+insulin Total   Percentage of patients needed additional insulin 
Ainuddin et al. 2015 a 43 32 75 43% 
Ainuddin et al. 2015 b 16 90 106 85% 
Goh et al. 2011 249 216 465 46% 
Hickman et al. 2012 8 6 14 43% 
Ijas et al. 2011 32 15 47 32% 
Niromanesh et al. 2012 69 11 80 14% 
Rowan et al. 2008 195 168 363 46% 
Tertti et al. 2013 87 23 110 21% 
Total 699 561 1260 45% 
Table S1. Percentage of patients in metformin group who were supplemented with additional insulin 
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a 
b 
Supplementary Figure S2: A meta-analysis comparing the risk ratio of pre-
eclampsia in metformin only vs. insulin treatment group. (A) A meta-analysis 
including both randomised controlled trials (RCTs) and cohort studies (CSs) 
comparing metformin only treatment to insulin only treatment. (B) A meta-
analysis including only RCTs comparing metformin only vs. insulin only 
treatment. 
 
Metformin only vs insulin only (RCTs and CSs) 
Metformin only vs insulin only (RCTs only) 
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